Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...

The U.S. Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as ...

The Food and Drug Administration approved a new vaccine to prevent HIV infection, lenacapavir, a long-acting injection, which ...

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

The United States Food and Drug Administration, FDA, has approved a new long-acting injectable drug, Lenacapavir, for the ...

The United States Food and Drug Administration (FDA) has approved a twice-a-year drug to be used to prevent HIV.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

PINE BELT, Miss. (WDAM) - The medical community has reached another milestone that could put an end to the decades-long HIV epidemic. The Food & Drug Administration approved Yeztugo (Lenacapavir) ...